• 1
    Levi F, Raymond L, Schüler G, Fisch T, Bouchardy C, Alleman J, et al. Cancer en Suisse. Faits et commentaires. Berne: Ligue Suisse contre le Cancer, 1998.
  • 2
    La Vecchia C, Lucchini F, Negri E, Boyle P, Maisonneuve P, Levi F. Trends in cancer mortality in Europe, 1955–1989: II. Respiratory tract, bone, connective and soft tissue sarcomas, and skin. Eur J Cancer 1992;28: 51499.
  • 3
    BerrinoF, SantM, VerdecchiaA, CapocacciaR, HakulinenT, EstèveJ, editors. Results. Lung. In Survival of cancer patients in Europe. The Eurocare Study. IARC Scientific Pub No. 132. Chapter 17. Lyon: International Agency for Research on Cancer, 1995: 23244.
  • 4
    Obradovic M, Fioretta G, Droin N, Raymond L, Bouchardy C. Le cancer à Genève. Incidence, mortalité, survie 1970–1994. Geneva: Département de l'action sociale et de la santé, Registre Genevois des Tumeurs, 1997.
  • 5
    Ferguson MK, Skosey C, Hoffman PC, Golomb HM. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol 1990; 8: 14027.
  • 6
    Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis J, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multi-variate analyses including recursive partioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 1995; 13: 122130.
  • 7
    Palomares MR, Sayre JW, Shekar KC, Lillington LM, Chlebowski RT. Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients. Cancer 1996; 78: 211926.
  • 8
    Bouchardy C. Switzerland, Geneva. In: ParkinDM, WhelanSL, FerlayJ, RaymondL, YoungJ, editors. Cancer incidence in five continents. Volume 7. IARC Scientific Pub No. 143. Lyon: International Agency for Research on Cancer, 1997: 6669.
  • 9
    World Health Organization. International classification of diseases for oncology, ICD-O. 1st edition. Geneva: World Health Organization, 1976.
  • 10
    Raymond L, Fischer B, Fioretta G, Bouchardy C. Migration bias in cancer survival rates. J Epidemiol Biostat 1996; 1: 16773.
  • 11
    World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Volume 1. Geneva: World Health Organization, 1967.
  • 12
    Summary Staging Guide for Cancer Surveillance, Epidemiology and End Results Reporting Program, April 1977. NIH Pub. No. 82-2313. In: ShambaughEM, WeissMA, AxtellLM, editors. Bethesda: U.S. Department of Health and Human Services, National Institutes of Health, 1982.
  • 13
    TNM Classification of Malignant Tumours. 2nd edition. Geneva: International Union Against Cancer, 1975.
  • 14
    TNM Classification of Malignant Tumours. 3rd edition. Geneva: International Union Against Cancer, 1978.
  • 15
    World Health Organization. Histologic typing of lung tumours. 2nd edition. Geneva: International Union Against Cancer, 1981.
  • 16
    Bureau fédéral de statistique. Classifications des professions, des situations dans la profession, des classes économiques. Mouvement de la population. Berne: Bureau fédéral de statistique, 1979.
  • 17
    Breslow NE, Day NE. The analysis of case-control studies. In: Statistical methods in cancer research. Volume 1. IARC Scientific Pub No. 32. Lyon: International Agency for Research on Cancer, 1980: 192242.
  • 18
    Francis B, Green M, Payne C, Swant T, Gilchrist R, Bradley M, et al., editors. The Statistical System for Generalized Linear Interactive Modelling, GLIM. Release 4 manual Oxford: Royal Statistical Society, 1993.
  • 19
    KealeyKA, HutchinsonF, editors. Centralized Cancer Patient Data System. Survival rates for U.S. comprehensive cancer center patients, admissions 1877–1982. Seattle: Cancer Research Center, 1985.
  • 20
    Johnson BE, Steinberg SM, Phelps R, Edison M, Veach SR, Ihde DC. Female patients with small cell lung cancer live longer than males patients. Am J Med 1988;85: 1946.
  • 21
    Noronha RFX, Goodall CM. Enhancement of hepatic and renal tumorigenesis in thyroidectomized NZR/Gd rats treated with dimethylnitrosamine. J Surg Oncol 1976; 8: 53950.
  • 22
    Lee YT. Better prognosis of many cancers in female: a phenomenon not explained by study of steroid receptors. J Surg Oncol 1984; 25: 25562.
  • 23
    Beattie CW, Hansen NW, Thomas PA. Steroid receptors in human lung cancer. Cancer Res 1985; 45: 420614.
  • 24
    Cagle PT, Mody DR, Schwartz MR. Estrogen and progesterone receptors in bronchogenic carcinoma. Cancer Res 1990; 50: 66325.
  • 25
    Mukhopadhyay T, Roth JA. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 1997; 14: 37984.
  • 26
    Vargas SO, Leslie KO, Vacek PM, Socinski MA, Weaver DL. Estrogen-receptor-related protein p29 in primary nonsmall cell lung carcinoma. Cancer 1998; 82: 1495500.
  • 27
    Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, et al. The endogenous oestronge mestabolite 2-methoxyostradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368: 2379.
  • 28
    Kubik A, Parkin DM, Khlat M, Erban J, Polak J, Adamec M. Lack of benefit from semi-annual screening for cancer of the lung: follow-up of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer 1990; 45: 2633.
  • 29
    Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR. Lung cancer screening: the Mayo program. J Occup Med 1986; 28: 74650.